D. Rubin
68 Papers
8 Citations
D. Rubin is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 36 publications.
Chat about Author
Papers
OP40 PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results
B.E. Sands,Laurent Peyrin-Biroulet,Silvio Danese,D. Rubin,Saar Vermeire,O. Laurent,Allison Luo,D. Nguyen,Anna Wiechowska-Kozłowska,Jaroslaw Leszczyszyn,Radosław Kempiński,Jaroslaw Kierkus,Timothy E. Ritter,BG Feagan,Stephan R. Targan +14 more
TL;DR: In this paper , PRA023 is an anti-TL1A monoclonal antibody in development for multiple inflammatory/fibrotic diseases using a precision medicine approach with a companion diagnostic (CDx).
OP33 Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): Results from the UPA Phase 3 programme
Jean-Frederic Colombel,Qian Cao,S. Ghosh,Walter Reinisch,W. Zhou,Dapo Ilo,Lan-di Shu,X Yao,D. Rubin +8 more
TL;DR: UPA treatment is effective in resolving EIMs in patients with UC and EIM symptom resolution was improved versus placebo following induction treatment with UPA 45 mg and after maintenance treatment withUPA 15 or 30 mg, with the 30 mg dose providing statistically significant improvements versus placebo.
OP24 Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn’s Disease: Week 48 analyses from the phase 2 GALAXI 1 study
Silvio Danese,Remo Panaccione,D. Rubin,B.E. Sands,Walter Reinisch,Geert R. D'Haens,Julián Panés,S. González,Kathleen M. Weisel,A. Sahoo,Mary Ellen Frustaci,Z. Yang,W J Sandborn,Anita Afzali,Tadanori Hisamatsu,Jane M. Andrews,BG Feagan +16 more
TL;DR: GUS induction followed by SC maintenance achieved high rates of clinical efficacy at Wk48 and key safety event rates were similar among GUS dose groups (Table 3); no opportunistic infections, cases of tuberculosis, or deaths were reported in any group.
17
OP16 Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn’s disease by number and type of prior biologics
Laurent Peyrin-Biroulet,G. Parkes,Cristina Rodríguez,Jesse S. Siffledeen,John Wright,Etty Broide,Shirin K. Ford,Ana P M Lacerda,J. Oomen,Amy Garrison,Sofie Berg,D. Rubin +11 more
TL;DR: In this paper, the outcomes of upadacitinib (UPA), an oral selective Janus kinase inhibitor, in patients with Crohn's disease who had failed a biologic, by the number and type of prior biologic therapies were assessed.
DOP44 Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis
Silvio Danese,Jean-Frederic Colombel,Terry Ponich,Igor Jovanović,Patrick M.M. Bossuyt,Randy S. Longman,Olga Alekseeva,Annkatrin Petersen,D. Chitkara,C. Marta,Lorna P. Charles,D. Rubin,Anita Afzali,E. Loftus,Douglas C. Wolf +14 more
TL;DR: UC pts from the phase 3 TN study demonstrated maintenance of response with long-term ozanimod treatment, with no new safety signals identified.
5